Metabolic tumor parameters complement clinicopathological factors in prognosticating advanced stage Hodgkin Lymphoma

Document Type : Original Article


1 Department of Nuclear medicine and Molecular Imaging, Tata Memorial Centre, Mumbai Maharashtra, India

2 Homi Bhabha National Institute, Anushaktinagar, Mumbai, Maharashtra, India

3 Department of Radiation Oncology, Tata Memorial Centre, Mumbai Maharashtra, India

4 Department of Haematooncology, Tata Memorial Centre, Mumbai Maharashtra, India


Objective(s): Advanced Hodgkin Lymphoma has a higher probability of relapse and recurrence. Classical clinicopathological parameters including the International Prognostic Score (IPS) have not been reliable in predicting prognosis or tailoring treatment.  Since FDG PET/CT is the standard of care in staging Hodgkin Lymphoma, this study attempted to evaluate the clinical utility of baseline metabolic tumor parameters in a cohort of advanced Hodgkin lymphoma (stage III and IV).
Methods: Histology-proven advanced Hodgkin Patients presenting to our institute between 2012-2016 and treated with chemo-radiotherapy (ABVD / AEVD) were followed up till 2019. Quantitative PET/CT and clinicopathological parameters were used to estimate the Event Free Survival (EFS) in 100 patients. Kaplan-Meier method with log-rank test was used to compare the survival times of prognostic factors.
Results: At a median follow-up of 48.83 months (IQR:33.31-63.05 months), the five-year-EFS was 81%. Of the 100 patients, 16 had relapsed (16%) and none died at the last follow-up. On Univariate analysis, among non-PET parameters bulky disease (P=0.03) and B-symptoms (P=0.04) were significant while among PET/CT parameters SUVmax (p=0.001), SUVmean (P=0.002), WBMTV2.5 (P<0.001), WBMTV41% (P<0.001), WBTLG2.5 (P<0.001) and WBTLG41% (P <0.001) predicted poorer EFS.  5-year EFS for patients with low WBMTV2.5 [<1038.3 cm3] was 89% and 35% for patients with high WBMTV2.5 [≥1038.3 cm3] (p <0.001). In a multivariate model, only WBMTV2.5 (P=0.03) independently predicted poorer EFS.
Conclusion: PET-based metabolic parameter (WBMTV2.5) was able to prognosticate and complement the classical clinical prognostic factors in advanced Hodgkin Lymphoma. This parameter could have a surrogate value for prognosticating advanced Hodgkin lymphoma. Better prognostication at baseline translates to tailored or risk-modified treatment and hence higher survival.


Main Subjects

  1. Jain H, Sengar M, Nair R, et al. Treatment results in advanced stage Hodgkin lymphoma: A retrospective study. J Postgrad Med. 2015; 61(2):88-91.
  2. Hodgkin Lymphoma - Cancer Stat Facts. SEER. Accessed April 18, 2020. https://seer.cancer. gov/statfacts/html/ hodg.html.
  3. Hasenclever D, DieHodgkin V. A prognostic score for advanced Hodgkin disease. International Prognostic Factors Project on Advanced Hodgkin Disease. N Engl J Med. 1998; 339(21):1506-1514.
  4. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin lymphoma: a report from a joint Italian-Danish study. J Clin Oncol Off J Am Soc Clin Oncol. 2007; 25(24):3746-3752.
  5. Kumar R, Maillard I, Schuster SJ, Alavi A. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin and non-Hodgkin lymphomas. Radiol Clin North Am. 2004; 42(6):1083-1100.
  6. Connors JM. Positron emission tomography in the management of Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program. 2011; 2011:317-322.
  7. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol Off J Am Soc Clin Oncol. 2014; 32(27):3059-3068.
  8. El-Galaly TC, d’Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography -staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2012; 30(36):4508-4514.
  9. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet Lond Engl. 2012; 379(9828):1791-1799.
  10. Borchmann P, Haverkamp H, Lohri A, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin lymphoma treated with BEACOPP-escalated alone or in combination with rituximab (HD18): an open-label, inter-national, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol. 2017; 18(4):454-463.
  11. Johnson P, Federico M, Kirkwood A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin Lymphoma. N Engl J Med. 2016; 374(25):2419-2429.
  12. André MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol Off J Am Soc Clin Oncol. 2017; 35(16):1786-1794.
  13. Barrington SF, Johnson PWM. 18F-FDG PET/CT in Lymphoma: Has imaging-directed personalized medicine become a reality? J Nucl Med. 2017; 58(10):1539-1544.
  14. Gobbi PG, Valentino F, Bassi E, et al. Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: Differences observed with 2 current chemotherapy regimens for advanced hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2011; 11(5):396-402.
  15. Specht L, Nordentoft AM, Cold S, Clausen NT, Nissen NI. Tumor burden as the most important prognostic factor in early stage Hodgkin disease. Relations to other prognostic factors and implications for choice of treatment. Cancer. 1988; 61(8): 1719-1727.
  16. Kostakoglu L, Chauvie S. Metabolic Tumor Volume Metrics in Lymphoma. Semin Nucl Med. 2018; 48(1):50-66.
  17. Holalkere N, Hochberg EP, Takvorian R, et al. Intensity of FDG uptake on PET scan varies by histologic subtype of hodgkin lymphoma. Blood. 2007; 110(11):4393.
  18. Akhtari M, Milgrom SA, Pinnix CC, et al.  Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood. 2018; 131(1):84-94.
  19. Song MK, Chung JS, Lee JJ, et al. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin lymphoma. Cancer Sci. 2013; 104(12): 1656-1661.
  20. Cottereau AS, Versari A, Loft A, et al. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood. 2018; 131(13):1456-1463.
  21. Kanoun S, Rossi C, Berriolo-Riedinger A, et al. Baseline metabolic tumor volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014; 41(9):1735-1743.
  22. Mettler J, Müller H, Voltin CA, et al. Metabolic Tumor Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma. J Nucl Med. 2019; 60(2):207-211.
  23. Moskowitz AJ, Schöder H, Gavane S, et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017; 130(20):2196-2203.
  24. Procházka V, Gawande RS, Cayci Z, et al. Positron Emission Tomography–Based Assessment of Metabolic Tumor Volume Predicts Survival after Autologous Hematopoietic Cell Transplantation for Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2018; 24(1):64-70.
  25. Casasnovas RO, Kanoun S, Tal I, et al. Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HODGKIN) enrolled in the AHODGKIN2011 LYSA trial. J Clin Oncol. 2016; 34(15_suppl):7509-7509.
  26. Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM procedure guidelines for tumor imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015; 42(2): 328-354.
  27. Cottereau AS, Versari A, Loft A, et al. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood. 2018; 131(13):1456-1463.
  28. Ceriani L, Martelli M, Zinzani PL, et al. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. 2015; 126(8):950-956.
  29. Meignan M, Cottereau AS, Versari A, et al. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. J Clin Oncol Off J Am Soc Clin Oncol. 2016; 34(30):3618-3626.
  30. Meignan M. Quantitative FDG-PET: a new biomarker in PMBCL. Blood. 2015; 126(8): 924-926.
  31. Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018; 93(5): 704-715.
  32. Kılıçkap S, Barışta İ, Ülger Ş, et al. Clinical Features and Prognostic Factors of Hodgkin Lymphoma: A Single Center Experience. Balk Med J. 2013; 30(2):178-185.
  33. Kostakoglu L, Chauvie S. Metabolic Tumor Volume Metrics in Lymphoma. Semin Nucl Med. 2018; 48(1):50-66.
  34. Specht L. Tumor burden as the main indicator of prognosis in Hodgkin disease. Eur J Cancer Oxf Engl 1990. 1992; 28A (12): 1982-1985.
  35. Gobbi PG, Ghirardelli ML, Solcia M, et al. Image-aided estimate of tumor burden in Hodgkin disease: evidence of its primary prognostic importance. J Clin Oncol Off J Am Soc Clin Oncol. 2001; 19(5):1388-1394.
  36. Zinzani PL, Broccoli A, Gioia DM, et al. Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. J Clin Oncol Off J Am Soc Clin Oncol. 2016; 34(12): 1376-1385.
  37. Press OW, Li H, Schöder H, et al. US Intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluoro-deoxyglucose-positron emission tomography imaging: Southwest oncology group S0816. J Clin Oncol Off J Am Soc Clin Oncol. 2016; 34(17):2020-2027.
  38. Pike LC, Kirkwood AA, Patrick P, et al. Can Baseline Pet-Ct Features Predict Outcomes in Advanced Hodgkin Lymphoma? A prospective evaluation of Uk patients in the rat hodgkin trial (cruk/07/033). Hematol Oncol. 2017; 35(S2):37-38.